Richard E. Champlin

Richard E. Champlin is a Professor of Medicine at The University of Texas MD Anderson Cancer Center. His research focuses on allogeneic hematopoietic cell transplantation, specifically optimizing donor selection and post-transplant management for hematological malignancies. His recent work investigates permissive HLA-DPB1 mismatches, TP53-mutant variant allele frequency in MDS/AML, and post-transplant cyclophosphamide prophylaxis. He also studies viral reactivation, including cytomegalovirus and Epstein-Barr virus, following transplantation, alongside maintenance therapies such as oral decitabine for myelodysplastic syndrome.